Company: SXTPW
Filing Date: 2025-08-15
Form Type: PRE 14A
Source: 0001213900-25-077435
Chunk: 51

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-08-15
Form: PRE 14A
Chunk 51
---

proceeds of disposition, if less) over the option exercise price. For capital gain treatment on such a disposition, the tax basis of the
shares will be their fair market value at the time of exercise.

Stock Appreciation Rights

A recipient does not recognize any taxable income
upon the receipt of a stock appreciation right (“SAR”). Upon the exercise of a SAR, the recipient will recognize ordinary
income in an amount equal to the excess of the fair market value of the underlying shares of common stock on the exercise date over the
exercise price.

Upon the exercise of a SAR, the Company will be
entitled to a corresponding income tax deduction in the tax year in which the SAR was exercised.

Equity Plan Information

The following chart reflects the number of securities
granted under equity compensation plans approved and not approved by stockholders and the weighted average exercise price for such plans
as of December 31, 2024:

| 2022 Equity Incentive Plan:                         |     | Number of securities to be issued upon exercise or issuance of outstanding options, units, warrants and rights(1): |       |     | Weighted average exercise price of outstanding options, warrants and rights(1) : |        |     | Number of securities remaining available for future issuance(1): |         |
|:----------------------------------------------------|:----|:-------------------------------------------------------------------------------------------------------------------|------:|:----|:---------------------------------------------------------------------------------|-------:|:----|:-----------------------------------------------------------------|--------:|
| Equity                                              
 compensation plans approved by security holders     |     |                                                                                                                    | 4,437 |     | $                                                                                | 116.07 |     |                                                                  | 154,392 |
| Equity                                              
 compensation plans not approved by security holders |     |                                                                                                                    |     — |     |                                                                                  |      — |     |                                                                  |       — |
| Total                                               |     |                                                                                                                    | 4,437 |     | $                                                                                | 116.07 |     |                                                                  | 154,392 |

| (1) | Balances presented as of December 
 31, 2024                          |

<div align='center'>The Board recommends that you vote “FOR” the approval to increase the total number of authorized shares
under the 2022 Equity Incentive Plan by 250,000 shares.

29

PROPOSAL 3</div>

TO APPROVE AN AMENDMENT TO OUR CERTIFICATE OF INCORPORATION TO EFFECT A REVERSE STOCK SPLIT OF OUR COMMON STOCK AT